Menu Search
Equities

Spectral Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SD4:FRA

Spectral Medical Inc

Actions
  • Price (EUR)0.78
  • Today's Change-0.04 / -4.88%
  • Shares traded46.00
  • 1 Year change+95.00%
  • Beta0.1499
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Spectral Medical Inc. is a Canada-based late-stage theranostic company focused on advancing therapeutic solutions for sepsis and septic shock. The Company develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The Company also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. It provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.

  • Revenue in CAD (TTM)2.71m
  • Net income in CAD-41.69m
  • Incorporated2005
  • Employees29.00
  • Location
    Spectral Medical Inc135 The West Mall, Unit 2TORONTO M9C 1C2CanadaCAN
  • Phone+1 (416) 626-3233
  • Fax+1 (416) 626-3233
  • Websitehttps://spectraldx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.